EYPT
Eyepoint Pharmaceuticals Inc
4.10$
+1.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Cash Flow
Eyepoint Pharmaceuticals Inc (EYPT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -240 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.1 | -5.4 | -9.3 | -9.3 | -21 | -21 | -5.1 | 9.9 | 9.9 | -3.2 | -9.0 | -8.7 | 10 | 10 | -16 | -20 | -22 | -57 | -14 | -50 | -65 | 1.9 | -126 | -240 | |
| 0.2 | 0.2 | 1.2 | 1.2 | 11 | 8.7 | 0.4 | 3.3 | 3.4 | 2.2 | 1.0 | 0.9 | 0.9 | 0.9 | 0.8 | 0.8 | 1.1 | 2.6 | 2.6 | 2.8 | 2.4 | 0.5 | 1.5 | 2.3 | |
| – | – | – | -0.5 | 0.8 | 0.8 | 0.0 | 1.5 | 2.1 | 1.4 | 1.3 | 1.4 | 2.0 | 2.2 | 2.5 | 2.5 | 4.0 | 4.6 | 5.5 | 7.4 | 14 | 12 | 37 | 28 | |
| – | – | – | – | – | – | – | – | – | 16 | 1.3 | 1.3 | 2.0 | 2.2 | 2.5 | 29 | 49 | 9.4 | 7.4 | 6.7 | 38 | – | – | – | |
| 0.3 | -0.3 | -0.3 | 2.5 | 1.2 | 13 | -10 | -4.0 | -4.0 | 1.2 | 0.7 | 0.4 | 1.0 | 2.1 | 0.3 | 0.2 | -0.9 | -13 | 20 | -1.7 | -3.0 | 59 | -28 | -34 | |
| 0.0 | 0.4 | 2.6 | 2.6 | 1.2 | 0.1 | 0.3 | 0.2 | 0.0 | 0.1 | 0.4 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.2 | 2.2 | 3.5 | 4.1 | 3.3 | |
| 0.0 | -0.4 | – | -4.1 | -4.1 | 1.8 | -0.3 | -2.1 | -9.5 | 0.6 | 6.4 | 0.1 | 0.1 | -4.5 | 14 | -17 | -17 | -0.2 | -0.4 | -33 | -17 | -3.3 | -219 | 69 | |
| – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -2.2 | – | – | – | 0.1 | 4.7 | 1.0 | 0.2 | 17 | 8.5 | 42 | -0.2 | -0.1 | -0.1 | -0.2 | -0.3 | -0.2 | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 20 | 20 | 20 | 19 | 20 | 26 | -15 | -0.1 | -0.7 | -41 | -0.1 | -0.1 | |
| 0.6 | 2.8 | 2.8 | 22 | 22 | 18 | 18 | 0.8 | 10 | 10 | 4.7 | 19 | 19 | 17 | 8.5 | 8.5 | 29 | 34 | 37 | 217 | -0.7 | 187 | 164 | 174 | |
| -2.6 | 21 | -14 | -14 | 1.9 | -10 | 13 | -8.7 | 8.6 | -2.6 | -8.3 | 2.3 | 8.4 | 3.8 | -3.8 | 1.6 | 22 | -23 | 23 | 134 | -83 | 186 | -182 | 2.1 | |
| -3.1 | -5.8 | -12 | -12 | -17 | -21 | -5.4 | -8.6 | 9.9 | -3.3 | -9.4 | -8.8 | -11 | 10 | -16 | -21 | -22 | -57 | -15 | -50 | -67 | -1.6 | -130 | -243 |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.